乙醯胺酚靜脈注射市場：按類型、按應用、按最終用戶、按地區

預計2024年全球乙醯胺酚注射市場規模為8.381億美元，預計2031年將達到10.541億美元，2024年至2031年複合年成長率為3.3%。

圖：2024 年乙醯胺酚靜脈注射液市場佔有率（%）

乙醯胺酚，也稱為對乙醯胺酚，是最常用的非處方止痛和退燒藥之一。主要用於治療頭痛、肌肉痛、背痛、牙痛、感冒、發燒。靜脈注射時，對乙醯胺酚比口服給藥時更快吸收到血液中。因此，靜脈注射適合吞嚥錠劑有困難或經歷劇烈疼痛的患者。癌症等慢性疾病的增加可能會增加靜脈注射乙醯胺酚溶液的需求，而癌症等慢性疾病的疼痛管理很重要。此外，新配方的快速核准和對疼痛管理日益成長的興趣可能會在預測期內為全球乙醯胺酚靜脈注射市場參與者提供利潤豐厚的機會。

市場動態

全球靜脈注射乙醯胺酚市場的成長主要是由全球老年人口不斷增加所推動的，老年人口更容易患慢性疾病和需要疼痛管理的損傷。根據世界衛生組織公佈的資料，到2024年10月1日，65歲及以上的人口預計將從2010年的估計5.24億增加到2050年的約15億。患有骨質疏鬆症和關節炎等痛苦疾病的老年人口不斷增加，增加了對強效止痛藥的需求。然而，市場成長可能會受到某些挑戰的阻礙，例如替代藥物的可用性以及長期使用靜脈注射乙醯胺酚相關的副作用風險。癌症研究的醫學進步導致更有效的治療方法的發現。這可能會增加對乙醯胺酚等靜脈鎮痛藥的需求，以控制化療引起的疼痛。此外，製藥公司對開發新型製劑的日益關注可能會為靜脈注射乙醯胺酚市場開闢新的途徑。

本研究的主要特點

本報告對全球乙醯胺酚靜脈注射劑市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、主要亮點、績效和策略等參數，包括全球乙醯胺酚靜脈注射市場的主要企業概況。

本研究涵蓋的主要企業包括強生公司、Fresenius Kabi AG、Baxter International Inc.、輝瑞公司、B. Braun Melsungen AG、Hikma Pharmaceuticals PLC、Amgen Inc.、Sandoz（諾華子公司）、Teva Pharmaceutical Industries Ltd.。 Mylan NV、Eton Pharmaceuticals, Inc.、Aurobindo Pharma Ltd.、Sun Pharmaceutical Industries Ltd.、Apotex Inc.、Mallinckrodt包括藥品。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。

乙醯胺酚靜脈注射全球市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

透過用於分析全球乙醯胺酚靜脈注射市場的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與前提

• 研究目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章 市場動態、法規與趨勢分析

• 市場動態
• 促進因素
• 抑制因素
• 機會
• 影響分析
• 主要進展
• 監管場景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景
• 產業動態

第4章全球乙醯胺酚靜脈注射市場，依類型，2019-2031

• 單一劑量
• 多劑量

第5章全球乙醯胺酚靜脈注射市場，依應用分類，2019-2031

• 疼痛管理
• 退燒

第6章 全球乙醯胺酚靜脈注射市場，依最終用戶分類，2019-2031

• 醫院
• 診所
• 家庭護理設置
• 其他

第7章全球乙醯胺酚靜脈注射市場，按地區，2019-2031

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第8章 競爭格局

• Johnson & Johnson
• Fresenius Kabi AG
• Baxter International Inc.
• Pfizer Inc.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Amgen Inc.
• Sandoz（a Novartis division）
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Eton Pharmaceuticals, Inc.
• Aurobindo Pharma Ltd.
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc.
• Mallinckrodt Pharmaceuticals

第9章 分析師建議

• 命運之輪
• 分析師觀點
• 一致的機會圖

第10章 參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global paracetamol IV market is estimated to be valued at USD 838.1 Mn in 2024 and is expected to reach USD 1,054.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031.

Figure. Paracetamol IV Market Share (%), By Region 2024

Paracetamol, also known as acetaminophen, is among the most commonly used over-the-counter pain reliever and fever reducer. It is primarily used for treating headaches, muscle aches, backaches, toothaches, colds, and fevers. The intravenous route enables faster absorption of paracetamol into the bloodstream compared to the oral route. This makes the intravenous formulation a suitable option for patients who have difficulty in swallowing tablets or are experiencing severe pain. Rising cases of chronic diseases such as cancer, where pain management is crucial, can boost the demand for paracetamol IV solutions. Furthermore, rapid approval of new formulations and growing focus on pain management can present lucrative opportunities for global paracetamol IV market players over the forecast period.

Market Dynamics

Global paracetamol IV market growth is primarily driven by rising geriatric population worldwide who are more susceptible to chronic illnesses and injuries requiring pain management. According to the data published by the WHO, on October 1, 2024, the number of people aged 65 years or older is projected to increase from an estimated 524 million in 2010 to nearly 1.5 billion in 2050. Growing incidence of painful conditions like osteoporosis and arthritis in the elderly population boosts the need for potent intravenous painkillers. However, market growth can be hampered by certain challenges such as availability of alternative drugs and risk of adverse effects associated with prolonged usage of paracetamol IV. Ongoing medical advances in cancer research leads to the discovery of more effective therapies. This can boost demand for intravenous analgesics like paracetamol for managing chemotherapy-induced pain. Moreover, increasing focus of pharmaceutical companies on developing novel drug formulations can open new avenues for the paracetamol IV market.

Key features of the study

This report provides in-depth analysis of the global paracetamol IV market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global paracetamol IV market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Johnson & Johnson, Fresenius Kabi AG, Baxter International Inc., Pfizer Inc., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Amgen Inc., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Mylan N.V., Eton Pharmaceuticals, Inc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., and Mallinckrodt Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global paracetamol IV market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global paracetamol IV market

Market Segmentation

• Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Single Dose
  • Multi-Dose
• Application Insights (Revenue, USD Mn, 2019 - 2031)
  • Pain Management
  • Fever Reduction
• End User Insights (Revenue, USD Mn, 2019 - 2031)
  • Hospitals
  • Clinics
  • Homecare Settings
  • Others
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Johnson & Johnson
  • Fresenius Kabi AG
  • Baxter International Inc.
  • Pfizer Inc.
  • B. Braun Melsungen AG
  • Hikma Pharmaceuticals PLC
  • Amgen Inc.
  • Sandoz (a Novartis division)
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Eton Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Apotex Inc.
  • Mallinckrodt Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Paracetamol IV Market, By Type
  • Global Paracetamol IV Market, By Application
  • Global Paracetamol IV Market, By End User
  • Global Paracetamol IV Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Paracetamol IV Market, By Type, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Single Dose
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Multi-Dose
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Paracetamol IV Market, By Application, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pain Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Fever Reduction
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Paracetamol IV Market, By End User, 2019-2031, (USD Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Homecare Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Paracetamol IV Market, By Region, 2019 - 2031, (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2020- 2031, (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fresenius Kabi AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• B. Braun Melsungen AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sandoz (a Novartis division)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eton Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aurobindo Pharma Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Apotex Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mallinckrodt Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us